Brussels, 24/10/2008 (Agence Europe) - On Thursday 23 October, the European Medicines Agency (EMEA) recommended to the European Commission that it should adopt a decision suspending marketing authorisation for Acomplia®, a medicine produced by Sanofi-Aventis to help obese and overweight people to lose weight. A study carried out by EMEA has in fact shown that obese or overweight patients treated with Acomplia® ran about twice as much risk of psychiatric disorders than those treated with a...